Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 6/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28503558 | 0.89 | KCNH2 (0.47) | KCNH2DRD2DRD1DRD4DRD5 | |
| SCHEMBL23720026 | 0.81 | GAA (0.45) | PDE3BPDE3AKDM4EALDH1A1HPGD | |
| SCHEMBL23700639 | 0.80 | KDM4E (0.42) | ADORA1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL21580842 | 0.76 | ADORA1 (0.43) | ADORA1KDM4EALDH1A1HPGDGLA | |
| SCHEMBL28507283 | 0.76 | DRD2 (0.39) | KDM4EDRD2DRD1DRD4DRD5 | |
| SCHEMBL21580812 | 0.72 | ALDH1A1 (0.46) | PDE3BPDE3AKDM4EALDH1A1HPGD | |
| SCHEMBL8613925 | 0.68 | TSHR (0.47) | ADORA1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL365010 | 0.68 | KDM4E (0.44) | ADORA1KDM4EALDH1A1HPGDGAA | |
| SCHEMBL12788120 | 0.67 | STS (0.47) | ADORA1KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL13316541 | 0.67 | LMNA (0.52) | PDE3BPDE3AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802549-B1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3802549-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| CN-112204037-A | Novel oxoquinolizine compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-01-08 | — | — | CN | disclosed |
| WO-2019228940-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238197-A1 | NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | O60361, ARG1, QDPR | PDE3B 1519/4885PDE3A 1671/4885ADORA1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.